25 recruiting. 25 Phase 2, 7 Phase 1, 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 25 | Recruiting 25 |
| Phase 1 | 7 | Recruiting 7 |
| Phase 3 | 2 | Recruiting 2 |
Follow Vasculitis: new trials by email Literature Review of Vasculitis trials Research Report on Vasculitis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| FT839 in Autoimmune Diseases FT839 - ANCA-Associated Vasculitis (AAV), Idiopathic Inflammatory Myositis (IIM) | Phase 1 / Phase 2 | Recruiting | Fate Therapeutics | 446 | 2026-10-01 | 2026-09-02 |
| Obinutuzumab Beta Combined With Low-dose Glucocorticoid in New-onset ANCA-Associated Glomerulonephritis Obinutuzumab beta, Glucocorticoids - ANCA-Associated Glomerulonephritis (AAGN), ANCA-Associated Vasculitis (AAV) | Phase 2 | Recruiting | Chinese PLA General Hospital | 20 | 2026-08-21 | 2026-09-15 |
| Evaluate the Effectiveness and Safety of BBD-1 Multi-target Immune Enhancement Targeting Agent in the Treatment of Hypersensitivity Reaction (IgA) Vasculitis BBD-1 Multi target Immune Enhancement Targeting Agent - Allergic Reaction (IgA) Vasculitis | Phase 2 | Recruiting | Qifeng Zhang | 30 | 2026-08-10 | 2026-08-11 |
| TAVNEOS for Otolaryngologic Manifestations of Granulomatosis With Polyangiitis Avacopan, Placebo - Granulomatosis With Polyangiitis, Wegener's | Phase 2 / Phase 3 | Recruiting | Robert Spiera, MD | 30 | 2026-05-22 | 2026-09-02 |
| Baricitinib in the Treatment of Kohlmeier-Degos Disease in Patients With Neurological Involvement Baricitinib - Kohlmeier-Degos Disease, Malignant Atrophic Papulosis | Phase 2 | Recruiting | National Heart, Lung, and Blood Institute (NHLBI) | 12 | 2026-02-18 | 2026-09-18 |
| Descartes-08 for Children, Adolescents, and Young Adults With Autoimmune Disorders Descartes-08 - Childhood-onset Systemic Lupus Erythematous, ANCA-Associated Vasculitis (AAV) | Phase 1 / Phase 2 | Recruiting | Cartesian Therapeutics | 50 | 2026-01-14 | 2026-07-27 |
| Tocilizumab Discontinuation Versus Dose Reduction for Patients With Well-Controlled Giant Cell Arteritis Tocilizumab, Discontinue Tocilizumab - Giant Cell Arteritis (GCA) | Phase 2 | Recruiting | National Institute of Allergy and Infectious Diseases (NIAID) | 78 | 2026-01-05 | 2026-08-10 |
| Obinutuzumab for Remission Induction in Patients With Relapsing PR3-ANCA Granulomatosis With Polyangiitis Obinutuzumab - Granulomatosis With Polyangiitis | Phase 2 | Recruiting | Assistance Publique - Hôpitaux de Paris | 33 | 2025-12-19 | 2026-03-06 |
| Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder Arthroplasty Methotrexate, Sulfasalazine, Hydroxychloroquine - Rheumatic Disease | Phase 2 | Recruiting | NYU Langone Health | 80 | 2025-12-12 | 2026-07-09 |
| Safety and Efficacy of Tarperprumig in Adult Participants With Anti-Neutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis Placebo, Tarperprumig - Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis | Phase 2 | Recruiting | Alexion Pharmaceuticals, Inc. | 75 | 2025-11-26 | 2026-06-16 |
| Pragmatic, Open-Label Study to Pilot Evaluation for Clinical Trials in Relapsing Polychondritis Methotrexate (MTX), Azathioprine (AZA), Adalimumab - Relapsing Polychondritis | Phase 2 | Recruiting | University of Pennsylvania | 20 | 2025-11-11 | 2026-09-02 |
| Safety and Efficacy of Universal CD19-targeting CAR-γδT Cells in Refractory Autoimmune Diseases anti-CD19 CAR T cell therapy - Systemic Lupus Erthematosus, Systemic Sclerosis (SSc) | Phase 1 / Phase 2 | Recruiting | Peking University Third Hospital | 9 | 2025-07-01 | 2026-09-22 |
| Dapagliflozin and Endothelin Receptor Antagonism in Large Vessel Vasculitis (DERAIL-LVV) Bosentan and dapagliflozin - Large Vessel Vasculitis, Giant Cell Arteritis (GCA) | Phase 2 | Recruiting | University of Edinburgh | 60 | 2025-03-21 | 2026-01-14 |
| A Clinical Trial to Investigate 18F-AzaFol in the Diagnosis of Large Vessel Vasculitis AzaFol, FDG - Giant Cell Arteritis | Phase 2 | Recruiting | Insel Gruppe AG, University Hospital Bern | 70 | 2025-02-03 | 2026-05-01 |
| BCMA-CD19 CAR-T Therapy for Refractory Autoimmune Diseases BCMA-CD19 CAR-T therapy - Systemic Lupus Erythematosus, Inflammatory Myopathy | Phase 2 | Recruiting | Peking University People's Hospital | 50 | 2024-12-26 | 2025-04-02 |
| Anti-CD19 CAR T-Cell Therapy in Refractory Systemic Autoimmune Diseases CAR T cell - Lupus Erythematosus, Systemic, System; Sclerosis | Phase 1 / Phase 2 | Recruiting | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | 8 | 2024-11-29 | 2025-04-11 |
| Baricitinib in the Treatment of Intestinal Behçet's Syndrome Baricitinib, Adalimumab - Behcet Syndrome, Intestinal Type | Phase 2 | Recruiting | Peking Union Medical College Hospital | 56 | 2024-11-08 | 2026-09-21 |
| A Phase 1/2 Study of NKX019 in Subjects With Immune-Mediated Diseases (Ntrust-2) NKX019, Fludarabine, Cyclophosphamide - Systemic Sclerosis, Idiopathic Inflammatory Myopathies | Phase 1 / Phase 2 | Recruiting | Nkarta, Inc. | 240 | 2024-11-04 | 2026-08-07 |
| Infliximab Therapy for Dolichoectactic Vertebrobasilar Aneurysms Infliximab - Aneurysm, Stroke | Phase 1 / Phase 2 | Recruiting | University of California, San Francisco | 8 | 2024-10-01 | 2026-06-11 |
| Fourth-gen CAR T Cells Targeting BCMA/CD19 for Refractory Systemic Lupus Erythematosus (SLE) CD19- BCMA CAR-T cells - Systemic Lupus Erythematosus, Lupus Nephritis | Phase 1 / Phase 2 | Recruiting | Essen Biotech | 75 | 2024-07-10 | 2024-10-15 |
Showing 20 of 25. Sign in to see all of them.
Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (9) · Myositis (6) · Lupus Erythematosus, Systemic (5) · Scleroderma, Systemic (5) · Behcet Syndrome (4) · Dermatomyositis (4) · Giant Cell Arteritis (4) · Granulomatosis with Polyangiitis (4) · Arthritis, Rheumatoid (3) · Polymyositis (3) · Sjogren's Syndrome (3) · Aneurysm (2) · Antiphospholipid Syndrome (2) · IgA Vasculitis (2)
Cardiovascular Diseases (25) · Vascular Diseases (25) · Skin and Connective Tissue Diseases (23) · Skin Diseases (22) · Skin Diseases, Vascular (22) · Immune System Diseases (20) · Autoimmune Diseases (17) · Nervous System Diseases (13) · Systemic Vasculitis (13) · Connective Tissue Diseases (10) · Musculoskeletal Diseases (10) · Muscular Diseases (9) · Neuromuscular Diseases (9) · Arthritis (6)
tocilizumab (4) · Adalimumab (3) · Azathioprine (3) · Infliximab (3) · Cyclophosphamide (2) · Methotrexate (2) · baricitinib (2) · tofacitinib (2) · Abatacept (1) · Bosentan (1) · Certolizumab Pegol (1) · Colchicine (1) · Cyclosporine (1) · Dapsone (1) · Etanercept (1)
Peking Union Medical College Hospital (2) · University of Pennsylvania (2) · Alexion Pharmaceuticals, Inc. (1) · Assistance Publique - Hôpitaux de Paris (1) · Cartesian Therapeutics (1) · Chinese PLA General Hospital (1) · Essen Biotech (1) · Fate Therapeutics (1) · Fondazione Policlinico Universitario Agostino Gemelli IRCCS (1) · Guangdong Hengrui Pharmaceutical Co., Ltd (1) · Insel Gruppe AG, University Hospital Bern (1) · NYU Langone Health (1) · National Heart, Lung, and Blood Institute (NHLBI) (1) · National Institute of Allergy and Infectious Diseases (NIAID) (1) · Nkarta, Inc. (1)
United States (12) · China (9) · Italy (3) · United Kingdom (3) · Australia (2) · Canada (2) · France (2) · Germany (2) · Netherlands (2) · Poland (2) · Spain (2) · Argentina (1) · Brazil (1) · Japan (1) · Puerto Rico (1)
Britta Maurer (1) · Christian Pagnoux, MD, MPH, MSc (1) · Cornelia D Cudrici, M.D. (1) · Daniel L Cooke, MD (1) · Jaap M van Laar, Prof. dr. (1) · Jonathan Samuels, MD (1) · Lindsay Lally, MD (1) · Maria Antonietta D'Agostino (1) · Radko Komers, MD, PhD (1) · Robert F Spiera, MD (1) · Robert Micheletti, MD (1) · Sebastian H Unizony, M.D. (1) · Shubhasree Banerjee, MD (1)
PMID 32345372, PMID 36853224, PMID 38724717, PMID 39915014, PMID 40938675, PMID 42384439
2025 (1), U54AR057319 (1)